Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Share Price (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
722.00    -2.00 (-0.28%)
Bid:
721.00
Ask:
769.00
Spread: 48.00 (6.657%)
Market Cap: £49.10m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Hemogenyx Pharmaceuticals Share Price
Price 722.00 Open 742.00
Bid 721.00 High 744.00
Ask 769.00 Low 719.00
Change -2.00 (-0.28%) Close 724.00
Volume 32,717
Currency GBX
Issue Country GB
Shares in Issue 6.80m
Market Cap £49.10m
PE Ratio -4.232122
EPS -170.60
Year High 1,790.00
Year High Date 17-Sep-2025
Year Low 124.50
Year Low Date 15-Jul-2025
Dividend 0.00
Yield 0.00%
# Trades 58
Vol. Sold 4,700
Sold Value £34.32k
Vol. Bought 9,131
Bought Value £67.70k
Market Size 500
What if I invested £1,000 in Hemogenyx Pharmaceuticals?
£ 1,054.01 (+5.40%)
1 month ago
£ 687.62 (-31.24%)
3 months ago
£ 1,556.03 (+55.60%)
6 months ago
£ 4,073.34 (+307.33%)
1 year ago
Add HEMO to WatchlistAdd HEMO to Watchlist

Compare Broker Offers

Selected partners may offer promotions for new customers. We may earn a referral fee if you open an account

Great for:
Active Traders
View Offer
Capital at risk
Great for:
Copy Trading
View Offer
Other fees apply.
Capital at risk.
Great for:
ISAs & SIPPs
View Offer
Capital at risk
Great for:
Beginner Friendly
View Offer
Capital at risk
Hemogenyx Pharmaceuticals Plc Ord Gbp0.01

Hemogenyx Pharmaceuticals is listed in the Medicine and Biotech sector.

Hemogenyx Pharmaceuticals Plc Ord Gbp0.01 is listed on the London Stock Exchange trading with ticker code HEMO.L. It has a market capitalisation of £49.10m, with approximately 6.80m shares in issue. Over the last year, Hemogenyx Pharmaceuticals share price has been traded in a range of 1,665.50, hitting a high of 1,790.00, and a low of 124.50.

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO) headquartered in London, with its US operating subsidiaries, Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New York City. The Company is a clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as platform technologies that it uses as engines for novel product development.

Some Videos You Might Like

What's Hot 14th April 2026


 

Completion of Purchase of t...


Recent Share Trades for Hemogenyx Pharmaceuticals (HEMO)

Date Time Trade Prc Volume Buy/Sell Bid Ask Value  
05-Jun-2616:35:25722.0042Sell*721.00769.00303.24UT Uncrossing Trade
05-Jun-2616:18:05745.001,125Buy*719.00749.008,381O Ordinary
05-Jun-2616:18:05719.00100Sell*719.00749.00719.00O Ordinary
Trade was executed as an SI
05-Jun-2616:08:52742.001,000Buy*719.00745.007,420O Ordinary
05-Jun-2616:03:22743.00172Buy*719.00745.001,278O Ordinary
05-Jun-2615:46:17742.50673Buy*719.00745.004,997O Ordinary
05-Jun-2615:44:33742.50673Buy*719.00745.004,997O Ordinary
05-Jun-2615:28:46742.501,225Buy*719.00745.009,096O Ordinary
05-Jun-2615:25:34742.5086Buy*719.00745.00638.55O Ordinary
05-Jun-2615:17:12743.00240Buy*719.00745.001,783O Ordinary

Directors Deals for Hemogenyx Pharmaceuticals (HEMO)

Announced Traded Action Notifier Price Currency Amount Holding
31-Dec-2031-Dec-20Notification of HoldingAlexis M. Sandler held the position of Non-Executive Director at the time of this trade.Alexis M. Sandler0.00075,090,685
31-Dec-2031-Dec-20Notification of HoldingVladislav Sandler Ph.D. held the position of CEO at the time of this trade.Vladislav Sandler Ph.D.0.00041,544,677
30-Jan-2030-Jan-20PlacingPeter Redmond held the position of Non-Executive Director at the time of this trade.Peter Redmond1.80GBX555,5565,596,270
03-Jul-1928-Jun-19Transfer FromAlexis M. Sandler held the position of Non-Executive Director at the time of this trade.Alexis M. Sandler0.001,066,667116,635,362
07-Feb-1805-Feb-18BuyVladislav Sandler Ph.D. held the position of CEO at the time of this trade.Vladislav Sandler Ph.D.2.37GBX26,80040,478,010